Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Stoll, Gautier ^a,b,c   Iribarren, Kristina ^a,b,c,d   Michels, Judith ^d   Leary, Alexandra ^d,e   Zitvogel, Laurence ^f,g,h   Cremer, Isabelle ^a,b,c   Kroemer, Guido ^b,c,d,i,j  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Universite Paris Sud   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g INSERM   (France)

^h Center of Clinical Investigations in Biotherapies of Cancer CICBT 507   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Calreticulin; colorectal cancer; cytotoxic T lymphocytes; dendritic cell; immunosurveillance; mammary carcinoma; non small cell lung cancer; ovarian cancer; prostate cancer

Indexed keywords

CALRETICULIN;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER PROGNOSIS; CELL INFILTRATION; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; MICROARRAY ANALYSIS; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION;

EID: 84976353299     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1177692     Document Type: Article

References (38)

1. W.A.Wang, J.Groenendyk, M.Michalak. Calreticulin signaling in health and disease. Int J Biochem Cell Biol 2012; 44:842-6; PMID:22373697; http://dx.doi.org/10.1016/j.biocel.2012.02.009
2. M.G.Coppolino, M.J.Woodside, N.Demaurex, S.Grinstein, R.St-Arnaud, S.Dedhar. Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 1997; 386:843-7; PMID:9126744; http://dx.doi.org/10.1038/386843a0
3. J.Groenendyk, M.Michalak. Disrupted WNT signaling in mouse embryonic stem cells in the absence of calreticulin. Stem Cell Rev 2014; 10:191-206; PMID:24415131; http://dx.doi.org/10.1007/s12015-013-9488-6
4. N.Mesaeli, K.Nakamura, E.Zvaritch, P.Dickie, E.Dziak, K.H.Krause, M.Opas, D.H.MacLennan, M.Michalak. Calreticulin is essential for cardiac development. J Cell Biol 1999; 144:857-68; PMID:10085286; http://dx.doi.org/10.1083/jcb.144.5.857
5. F.Rauch, J.Prud'homme, A.Arabian, S.Dedhar, R.St-Arnaud. Heart, brain, and body wall defects in mice lacking calreticulin. Exp Cell Res 2000; 256:105-11; PMID:10739657; http://dx.doi.org/10.1006/excr.2000.4818
6. L.Guo, J.Lynch, K.Nakamura, L.Fliegel, H.Kasahara, S.Izumo, I.Komuro, L.B.Agellon, M.Michalak. COUP-TF1 antagonizes Nkx2.5-mediated activation of the calreticulin gene during cardiac development. J Biol Chem 2001; 276:2797-801; PMID:11106640; http://dx.doi.org/10.1074/jbc.C000822200
7. B.Sadasivan, P.J.Lehner, B.Ortmann, T.Spies, P.Cresswell. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996; 5:103-14; PMID:8769474; http://dx.doi.org/10.1016/S1074-7613(00)80487-2
8. C.Andrin, M.J.Pinkoski, K.Burns, E.A.Atkinson, O.Krahenbuhl, D.Hudig, S.A.Fraser, U.Winkler, J.Tschopp, M.Opas et al. Interaction between a Ca2+-binding protein calreticulin and perforin, a component of the cytotoxic T-cell granules. Biochemistry 1998; 37:10386-94; PMID:9671507; http://dx.doi.org/10.1021/bi980595z
9. S.Sipione, C.Ewen, I.Shostak, M.Michalak, R.C.Bleackley. Impaired cytolytic activity in calreticulin-deficient CTLs. J Immunol 2005; 174:3212-9; PMID:15749851; http://dx.doi.org/10.4049/jimmunol.174.6.3212
10. S.J.Gardai, K.A.McPhillips, S.C.Frasch, W.J.Janssen, A.Starefeldt, J.E.Murphy-Ullrich, D.L.Bratton, P.A.Oldenborg, M.Michalak, P.M.Henson. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123:321-34; PMID:16239148; http://dx.doi.org/10.1016/j.cell.2005.08.032
11. M.Obeid, A.Tesniere, F.Ghiringhelli, G.M.Fimia, L.Apetoh, J.L.Perfettini, M.Castedo, G.Mignot, T.Panaretakis, N.Casares et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
12. M.Obeid, A.Tesniere, T.Panaretakis, R.Tufi, N.Joza, P.van Endert, F.Ghiringhelli, L.Apetoh, N.Chaput, C.Flament et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 2007; 220:22-34; PMID:17979837; http://dx.doi.org/10.1111/j.1600-065X.2007.00567.x
13. T.Panaretakis, N.Joza, N.Modjtahedi, A.Tesniere, I.Vitale, M.Durchschlag, G.M.Fimia, O.Kepp, M.Piacentini, K.U.Froehlich et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15:1499-509; PMID:18464797; http://dx.doi.org/10.1038/cdd.2008.67
14. E.Vacchelli, Y.Ma, E.E.Baracco, A.Sistigu, D.P.Enot, F.Pietrocola, H.Yang, S.Adjemian, K.Chaba, M.Semeraro et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 2015; 350:972-8; PMID:26516201; http://dx.doi.org/10.1126/science.aad0779
15. G.C.Brown, A.Vilalta, M.Fricker. Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology. Curr Mol Med 2015; 15:842-51; PMID:26511705; http://dx.doi.org/10.2174/156652401509151105130628
16. F.Aranda, N.Bloy, L.Galluzzi, G.Kroemer, L.Senovilla. Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. Oncoimmunology 2014; 3:e955685; PMID:25941619; http://dx.doi.org/10.4161/21624011.2014.955685
17. F.Aranda, N.Bloy, J.Pesquet, B.Petit, K.Chaba, A.Sauvat, O.Kepp, N.Khadra, D.Enot, C.Pfirschke et al. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene 2015; 34:3053-62; PMID:25065595; http://dx.doi.org/10.1038/onc.2014.234
18. M.Michaud, X.Xie, J.M.Bravo-San Pedro, L.Zitvogel, E.White, G.Kroemer. An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology 2014; 3:e944047; PMID:25610726; http://dx.doi.org/10.4161/21624011.2014.944047
19. L.Senovilla, I.Vitale, I.Martins, M.Tailler, C.Pailleret, M.Michaud, L.Galluzzi, S.Adjemian, O.Kepp, M.Niso-Santano et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
20. A.Q.Sukkurwala, S.Adjemian, L.Senovilla, M.Michaud, S.Spaggiari, E.Vacchelli, E.E.Baracco, L.Galluzzi, L.Zitvogel, O.Kepp et al. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology 2014; 3:e28473; PMID:25050214; http://dx.doi.org/10.4161/onci.28473
21. R.Q.Peng, Y.B.Chen, Y.Ding, R.Zhang, X.Zhang, X.J.Yu, Z.W.Zhou, Y.X.Zeng, X.S.Zhang. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol 2010; 16:2428-34; PMID:20480531; http://dx.doi.org/10.3748/wjg.v16.i19.2428
22. J.Fucikova, E.Becht, J.Goc, C.Iribarren, R.Remark, D.Damotte, M.Alifano, P.Devi, J.Biton, C.Germain et al. Calreticulin is a powerful prognostic marker for survival of non-small-cell lung cancer patients. Cancer Res. 2016 Apr 1; 76(7):1746-56; PMID:26842877; http://dx.doi.org/10.1158/0008-5472
23. K.Shedden, J.M.Taylor, S.A.Enkemann, M.S.Tsao, T.J.Yeatman, W.L.Gerald, S.Eschrich, I.Jurisica, T.J.Giordano, D.E.Misek et al. Gene expression-based survival prediction in lung adenocarcinoma:a multi-site, blinded validation study. Nat Med 2008; 14:822-7; PMID:18641660; http://dx.doi.org/10.1038/nm.1790
24. G.Stoll, G.Bindea, B.Mlecnik, J.Galon, L.Zitvogel, G.Kroemer. Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget 2015; 6:11894-909; PMID:26059437; http://dx.doi.org/10.18632/oncotarget.4180
25. J.Galon, H.K.Angell, D.Bedognetti, F.M.Marincola. The continuum of cancer immunosurveillance:prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008
26. A.S.Musahl, X.Huang, S.Rusakiewicz, E.Ntini, A.Marsico, G.Kroemer, O.Kepp, U.A.Ørom. A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription. Oncogene 2015; 34:5046-54; PMID:25579178; http://dx.doi.org/10.1038/onc.2014.424
27. A.D.Garg, S.Elsen, D.V.Krysko, P.Vandenabeele, P.de Witte, P.Agostinis. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget 2015; 6:26841-60; PMID:26314964; http://dx.doi.org/10.18632/oncotarget.4754
28. S.Ladoire, D.Enot, L.Senovilla, F.Ghiringhelli, V.Poirier-Colame, K.Chaba, M.Semeraro, M.Chaix, F.Penault-Llorca, L.Arnould et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016 May 3; 12(5):864-75; PMID:26979828; http://dx.doi.org/10.1080/15548627.2016.1154244
29. S.Ladoire, F.Penault-Llorca, L.Senovilla, C.Dalban, D.Enot, C.Locher, N.Prada, V.Poirier-Colame, K.Chaba, L.Arnould et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy 2015; 11:1878-90; PMID:26506894; http://dx.doi.org/10.1080/15548627.2015.1082022
30. A.Snyder, V.Makarov, T.Merghoub, J.Yuan, J.M.Zaretsky, A.Desrichard, L.A.Walsh, M.A.Postow, P.Wong, T.S.Ho et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498
31. R Development Core Team. R:A Language and Environment for Statistical Computing. Vienna, Austria, 2008.
32. L.Gautier, L.Cope, B.M.Bolstad, R.A.Irizarry. affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (Oxford, England) 2004; 20:307-15; PMID:14960456; http://dx.doi.org/10.1093/bioinformatics/btg405
33. M.I.Love, W.Huber, S.Anders. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15:550; PMID:25516281; http://dx.doi.org/10.1186/s13059-014-0550-8
34. M.E.Ritchie, B.Phipson, D.Wu, Y.Hu, C.W.Law, W.Shi, G.K.Smyth. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43:e47; PMID:25605792; http://dx.doi.org/10.1093/nar/gkv007
35. G.Stoll, D.Enot, B.Mlecnik, J.Galon, L.Zitvogel, G.Kroemer. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology 2014; 3:e27884; PMID:24790795; http://dx.doi.org/10.4161/onci.27884
36. C.Fraley, A.E.Raftery. Model-based clustering, discriminant analysis and density estimation. J Am Statistical Association 2002; 97:611-31; http://dx.doi.org/10.1198/016214502760047131
37. T.M.Therneau, P.M.Grambsch. Modeling Survival Data:Extending the Cox Model. New York:Springer, 2000.
38. Therneau T. (2015). A Package for Survival Analysis in S. version 2.38. http://CRAN.R-project.org/package=survival.